Helius Medical Technologies, Inc. Share Price Toronto S.E.

Equities

HSM

US42328V1089

Advanced Medical Equipment & Technology

Delayed Toronto S.E. 5-day change 1st Jan Change
- CAD -.--% Intraday chart for Helius Medical Technologies, Inc. +4.21% -.--%

Financials

Sales 2024 * 703K 957K 58.42M Sales 2025 * 1.31M 1.78M 109M Capitalization 4.18M 5.69M 347M
Net income 2024 * -10M -13.61M -831M Net income 2025 * -14M -19.06M -1.16B EV / Sales 2024 * 5.94 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 3.2 x
P/E ratio 2024 *
-0.26 x
P/E ratio 2025 *
-0.47 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.22%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 58 04/17/04
Director of Finance/CFO 63 09/20/09
Chief Tech/Sci/R&D Officer 57 08/21/08
Members of the board TitleAgeSince
Director/Board Member 85 18/14/18
Chief Executive Officer 58 04/17/04
Chairman 53 29/15/29
More insiders
Helius Medical Technologies, Inc. is a neurotech company in the medical device field. It is focused on neurologic deficits using orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms enhancing the lives of people dealing with neurologic diseases. It develops, licenses, or acquires non-implantable technologies targeted at reducing symptoms of neurological disease or trauma. Its product Portable Neuromodulation Stimulator (PoNS) is a non-implantable medical device, inclusive of a controller and mouthpiece, which delivers mild electrical stimulation to the surface of the tongue to provide treatment of gait deficit and chronic balance deficit. PoNS Therapy is integral to the overall PoNS solution and is the physical therapy applied by patients during use of the PoNS neuromodulation stimulator. PoNS is used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.41 USD
Average target price
4 USD
Spread / Average Target
+183.69%
Consensus